期刊
EJNMMI RESEARCH
卷 1, 期 -, 页码 -出版社
SPRINGEROPEN
DOI: 10.1186/2191-219X-1-1
关键词
-
资金
- NIH, National Cancer Institute, Center for Cancer Research
- NATIONAL CANCER INSTITUTE [ZIASC006353] Funding Source: NIH RePORTER
Background: The objective of this study was to characterize the in vitro and in vivo properties of the F(ab')(2) fragment of panitumumab and to investigate its potential for imaging and radioimmunotherapy. Methods: The panitumumab F(ab')(2) was generated by enzymatic pepsin digestion. After the integrity and immunoreactivity of the F(ab')(2) was evaluated, the fragment was radiolabeled. In vivo studies included direct quantitation of tumor targeting and normal organ distribution of the radiolabeled panitumumab F(ab')(2) as well as planar gamma-scintigraphy and PET imaging. Results: The panitumumab F(ab')(2) was successfully produced by peptic digest. The F(ab')(2) was modified with the CHX-A-DTPA chelate and efficiently radiolabeled with either In-111 or Y-86. In vivo tumor targeting was achieved with acceptable uptake of radioactivity in the normal organs. The tumor targeting was validated by both imaging modalities with good visualization of the tumor at 24 h. Conclusions: The panitumumab F(ab')(2) fragment is a promising candidate for imaging of HER1-positive cancers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据